Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib

Objective: The efficacy of anlotinib as a treatment for head-and-neck squamous cell carcinoma (HNSCC) has been little explored. Here, we used patient-derived xenografts (PDXs) to this end. Methods: Fresh tumor tissues of HNSCC patients were screened in terms of in vitro drug sensitivity using the MT...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Fangling, Guo, Liang, Yu, Jieqing, Dai, Daofeng, Xiong, Yuanping, He, Yuanqiao, Zhou, Wensheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696349/
https://www.ncbi.nlm.nih.gov/pubmed/34955687
http://dx.doi.org/10.3389/pore.2021.1610008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696349/
https://www.ncbi.nlm.nih.gov/pubmed/34955687
http://dx.doi.org/10.3389/pore.2021.1610008

Ejemplares similares